Life Science Leader - Home Page
WEBVolastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow. OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in ...
Merck's Continuous Process Improvement - Life Science Leader
WEBJul 1, 2014 · Merck embraced a process of continuous improvement after years of implementing Lean initiatives that yielded periodic improvements. With Lean, Six Sigma, Kaizen, Agile, total quality management, and other process improvement approaches, after an initial surge, results sometimes slipped backwards to baseline levels.
The Story Of Arrowhead Pharmaceuticals' Adversity Odyssey
WEBApr 1, 2020 · It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C., focused on creating and building new nanobiotechnology companies from university-generated science. “We talked about the deal, and then they ...
FSP Or Full-Service Outsourcing For Clinical Trials? - Life Science …
WEBDec 3, 2013 · Functional service provider (FSP) partnerships have been gaining traction in recent years because of their potential to increase efficiency and flexibility in outsourcing without compromising quality. Well-defined services within the scope of a clinical trial project or program (e.g. data management, biostatistics, or medical writing) are good ...
Why Takeda Is Focusing So Much On Plasma-Derived Therapies
WEBFeb 1, 2023 · Why Takeda Is Focusing So Much On Plasma-Derived Therapies. By Ben Comer, Chief Editor, Life Science Leader. He has nothing against the U.K., his native country, but Giles Platford, president of Takeda’s plasma-derived therapies (PDT) business unit and a member of the company’s executive leadership team, hasn’t lived there in …
Life Science Connect Podcast
WEBJun 25, 2021 · On today’s episode of the Life Science Connect podcast, Clinical Leader Chief Editor Ed Miseta talks about a virtual conference on patient centricity called “Focus On Patients,” covering the successes and challenges of putting patients at the center of clinical trials. 001: The JPM Conference. In this episode, Life Science Leader magazine ...
Where Are They Now? Roivant - Life Science Leader
WEBJan 15, 2024 · By Ben Comer, Chief Editor, Life Science Leader. Vivek Ramaswamy. Then: During the J.P. Morgan Healthcare conference in 2017, former Life Science Leader chief editor Rob Wright sat down with Roivant Sciences founder and CEO Vivek Ramaswamy to learn about the company’s plan to rescue abandoned drug candidates, while also reducing the average time and cost of development.
How To Navigate Pharma Collaboration And Licensing Agreements
WEBFeb 1, 2017 · More and more, biotech and pharmaceutical companies are taking active steps to (1) avoid collaboration and licensing disputes; and (2) resolve disputes that do arise without resorting to litigation. There is a variety of nonlitigation strategies to help companies navigate the uncertainties surrounding collaboration and licensing arrangements ...
Digital Transformation In The Life Sciences The C-Suite Weighs In
WEBFeb 28, 2020 · Our survey found that progress is being made when it comes to implementing digital automation in the life sciences sector: 30 percent said some of their processes have been automated, 48 percent have started limited implementations, and 23 percent are doing pilot programs for AI. While CEOs are …
How To Avoid Data-Integrity Woes In Pharma - Life Science Leader
WEBNov 1, 2019 · WHAT STEPS TO TAKE. The following items should be addressed to establish an understanding and mitigation of enterprise risks as they pertain to data integrity: Review internal product and process data systems to confirm data integrity and reliability (e.g., via an audit, determine if GMP rules are being followed, if systems are validatable, and ...